Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9NQX0

UPID:
PRDM6_HUMAN

ALTERNATIVE NAMES:
PR domain zinc finger protein 6; PR domain-containing protein 6

ALTERNATIVE UPACC:
Q9NQX0; B5MCJ4; Q9NQW9

BACKGROUND:
The protein PRDM6, alternatively named PR domain-containing protein 6, is implicated in the regulation of vascular smooth muscle cell phenotype. It suppresses differentiation and maintains the proliferative potential of these cells, while also affecting endothelial cell behavior. The debate over its histone methyltransferase activity highlights the complexity of its function in epigenetic transcriptional repression, specifically through 'Lys-20' methylation of histone H4.

THERAPEUTIC SIGNIFICANCE:
Given PRDM6's critical role in the pathogenesis of Patent ductus arteriosus 3, a congenital heart defect, targeting this protein could lead to innovative treatments. The exploration of PRDM6's function offers promising avenues for developing new therapeutic strategies in heart disease management.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.